Zyngenia, Inc
Zyngenia, Inc

Zyngenia, Inc Information

Contact top employees from Zyngenia, Inc

Summary

Zyngenia, Inc is a private company that has been in the industry for 16 years. The company currently specializes in the Biotechnology, Biotechnology areas. The position of the CEO is occupied by Andrey Kolokoltsov. Its headquarters is located at Washington, District of Columbia, USA. The number of employees ranges from 1 to 25. The annual revenue of Zyngenia, Inc varies between 5.0M and 25M. Total funding of the company - $43M. To connect with Zyngenia, Inc employee register on SignalHire.

Industries

Biotechnology

Headquarters Location

Employees Size

10-50 employees

Specialties

Single-Protein Combination Therapeutics

SIC Code

2836

DMA Code

Washington Metropolitan Area

Founded

2009

Estimated Annual Revenue

$5.0M - 25M

Operating Status

Independent Company

Contact Zyngenia, Inc

Organization Website

Social Links

linkedInfacebook

Competitors

Founded
Type
Employees
Revenue
Funding
2000Privately
Held
25 - 100 4.1M $3M
2008Public
Company
100 - 250 64M $302.6M
1996Public
Company
25 - 100 < 1M $160M
2003Privately
Held
25 - 100 5M $58.4M
-Privately
Held
100 - 250 37.3M $0
1977- 100 - 250 31.7M $0
2009- 100-200 - $-

Employees Turnover 3 quarter 2025

Length of Employment
arrow
Employee tenure at Zyngenia, Inc shows a diverse range of experience levels:
22% for 8–10 years78% have over 11 years of service at Zyngenia, Inc
Contact top employees from Zyngenia, Inc
Dan Crossan
Research Associate GLP Assay Development
View
barrack minna
Costumer support
View
Geping Wang
Associate Scientist
View
Mike Hayes
HR Coordinator
View

FAQ

Zyngenia, Inc operates in the Biotechnology industries. More details can be found on the official website: zyngenia.com.
The headquarters of Zyngenia, Inc are located in Gaithersburg, United States.
The current CEO of Zyngenia, Inc is Andrey Kolokoltsov
Zyngenia, Inc currently employs 10-50 people.
Zyngenia, Inc's revenue is approximately 5M.
Well-known competitors of Zyngenia, Inc include Parion Sciences, G1 Therapeutics, Inc., Endocyte and Atox Bio.
BACK TO TOP